Navigation Links
Abbott Receives FDA Approval for First Automated Molecular Test for Assessing Hepatitis B Treatment

DES PLAINES, Ill., Sept. 1 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT) announced today it has received approval from the U.S. Food and Drug Administration (FDA) to market the Abbott RealTime HBV assay for measuring viral load or the amount of hepatitis B virus (HBV) in a patient's blood. It is the first and only approved test capable of automating HBV viral load testing from sample extraction to final results.

The Abbott RealTime HBV assay, based on real-time PCR (polymerase chain reaction) technology, is now available for laboratories that use the Abbott m2000 automated instrument system for molecular diagnostic testing. The test offers sensitive measurement (quantitation) of HBV in human plasma or serum from individuals chronically infected with HBV.

The assay is intended for use as an aid in the management of patients with chronic HBV infection undergoing anti-viral therapy. The assay can be used to measure HBV DNA levels at baseline and during treatment to aid in assessing response to treatment.  Assay results must be interpreted within the context of all relevant clinical and lab findings.  Use of the assay to determine the clinical stage of HBV infection has not been established.  Clinical performance characteristics have been established for individuals treated with adefovir dipivoxil.  The assay is not intended as a screening test for HBV or as a diagnostic test for confirming the presence of HBV infection.  

"The Abbott RealTime HBV assay, which is the first and only automated HBV viral load test approved by the FDA, is an important tool for helping physicians make and adjust treatment decisions for newly diagnosed patients and those taking anti-viral medications," said Stafford O'Kelly, head of Abbott's molecular diagnostics business.  "The test will also help improve laboratory productivity by automating the most labor intensive steps of HBV testing."

Abbott's molecular HBV assay detects and measures all known HBV genotypes (A-H) by targeting an essential, highly conserved segment of the HBV genome.  The capability for detecting HBV genotypes is important for both monitoring the disease and guiding treatment decisions.  For example, genotype C is prevalent in Asia and is associated with more severe liver disease and development of hepatocellular carcinoma.  In contrast, genotype B (also prevalent in Asia) has a better prognosis, is rarely associated with progression to liver cancer, and patients seem to respond better to certain antiviral therapies. Immigration and international travel have increased the incidence of HBV strains predominantly found outside the United States.

In addition, the Abbott RealTime HBV assay offers a broad dynamic range, capable of quantitating both very low levels of the virus (10 IU/mL) and very high levels of the virus (1 billion IU/mL) in a patient's blood.  This broad dynamic range is an important factor in helping physicians accurately assess a patient's response to therapy.

The Abbott RealTime HBV assay, initially introduced in Europe and other markets in 2007, was developed for use on the Abbott m2000 system, an automated instrument for DNA and RNA testing.  The m2000 is designed to efficiently detect viruses and bacteria in patient samples in less than six hours.  The Abbott m2000 instrument is available in most major markets throughout the world. Outside the United States, an extensive menu for infectious disease testing is available that includes HIV-1 viral load, HBV viral load, chlamydia, chlamydia/gonorrhea (CT/NG) combination, hepatitis C (HCV) viral load, HCV genotyping, cytomegalovirus (CMV), Epstein Barr virus (EBV) and human papillomavirus (HPV).  In December 2009, Abbott Molecular introduced the first oncology assay on its m2000 system outside the United States — the Abbott RealTime mS9 Colorectal Cancer — that detects the methylated form of Septin 9, a gene linked to colorectal cancer, in blood specimens.  In the United States, the following tests are currently available on the m2000 platform: RealTime HIV-1, CT/NG, and now HBV.  

About Hepatitis B

According to the World Health Organization, hepatitis B is a serious global public health problem, but preventable with safe and effective vaccines that have been available since 1982.  Of the two billion people who have been infected with the hepatitis B virus, more than 350 million have chronic (lifelong) infections.  These chronically infected persons are at high risk of death from cirrhosis of the liver and liver cancer, diseases that kill about one million people each year.  Although the vaccine will not cure chronic hepatitis, it is 95 percent effective in preventing chronic infections from developing.  

The prevalence of HBV infection and the method of transmission vary greatly around the world.  In countries with a high prevalence of chronic HBV infection, the most common route of infection is from mother to child at birth or from child to child during early childhood.  In areas of low prevalence, the infection is usually acquired during adulthood through intravenous drug use or high-risk sexual activity.

About Abbott Molecular

Abbott Molecular,, is an emerging leader in molecular diagnostics - the analysis of DNA, RNA, and proteins at the molecular level. Some of Abbott Molecular's tests are designed to detect subtle but key changes in human genes and chromosomes.  The results of these tests may aid in the earlier detection or diagnosis of disease, may influence the selection of appropriate therapies, or may improve monitoring of disease recurrence.  

About Abbott

Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics.  The company employs approximately 83,000 people and markets its products in more than 130 countries.

Abbott's news releases and other information are available on the company's Web site at

Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
2. Abbott and AstraZeneca Announce Selection of Next-Generation Fenofibrate ABT-335 and CRESTOR(R) Fixed-Dose Combination
3. Abbott Initiates Clinical Study to Evaluate Use of RX Herculink(R) Elite(TM) Renal Stent System for the Treatment of Renal Artery Stenosis
4. Abbotts ABT-874 Shows Positive Results for Maintenance of Response in Phase II Psoriasis Study
5. Abbotts XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
6. Abbott Announces Positive One-Year Results from the Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
7. Abbotts m2000(TM) Molecular Diagnostic Instrument and RealTime HIV-1 Test Win Chicago Innovation Award
8. Abbotts HUMIRA(R) (adalimumab) Receives FDA Approval For Moderate to Severe Chronic Plaque Psoriasis
9. Abbotts XIENCE(TM) V Drug Eluting Stent Demonstrates Consistent and Positive Clinical Outcomes Out to Two Years
10. Abbotts Phase III Studies of Investigational TriLipix(TM) (ABT-335), in Combination With Statins, Meets Primary Endpoints on Improving LDL, Triglycerides and HDL
11. Study in JAMA Shows Patients Treated With Abbotts XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent
Post Your Comments:
(Date:11/30/2015)... Wash. , Nov. 30, 2015  Precision ... Post-Processing services, is pleased to announce a dramatic ... medical imaging services. Building on its ISO-9001:2008 certification ... and implemented comprehensive Core Lab protocols and procedures. ... variety of research activities.  Their Core Lab services ...
(Date:11/30/2015)... , November 30, 2015 Mexico Healthcare ... and Life Sciences Report 2015 . --> Pharmaboardroom releases ... . Latin America , a country of ... , a country of over 122 million people. --> ... healthcare, pharmaceuticals, or life sciences insights into the second largest pharma ...
(Date:11/30/2015)... TEL AVIV, Israel , November 30, 2015 /PRNewswire/ ... EMITF ) ("Elbit" or the "Company") announced today that it ... Ministry of Food and Drug Safety (MFDS) has approved ... behavioral disorders. --> --> ... presenting a non-invasive treatment alternative that combines two technologies: ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... November 30, 2015 , ... Workstation ... more than 30 HealthPostures’ dealers located throughout the United States, is OneStop Ergonomics. ... of corporate, industrial, manufacturing and government workers and organizational leaders that are introduced ...
(Date:11/30/2015)... ... November 30, 2015 , ... World Patent ... Unstoppable Swappables, a household invention that provides an economical and easy way of ... and is growing at 2.6%," says Scott Cooper, CEO and Creative Director of ...
(Date:11/30/2015)... ... November 30, 2015 , ... CTI Group (Holdings) ... empower organizations through communication analytics, announced today that their Proteus® VoIP QMS solution ... service quality. , Proteus® VoIP QMS (Quality Management System) does this ...
(Date:11/29/2015)... ... November 29, 2015 , ... ... Institute of Ultrasound in Medicine! , AIUM ultrasound practice accreditation is a ... or exceed nationally recognized standards in the performance and interpretation of diagnostic ...
(Date:11/29/2015)... ... November 30, 2015 , ... The Cyber Monday deal is a deep 40% or more ... time to get gifts for the skin care lover in your circle. Each Christmas, ... . This year, the 3 serums are staples: Collagen, Retinol and Hyaluronic Serums. , Stocking ...
Breaking Medicine News(10 mins):